MA vs MRK: Which Is the Better Buy?
Side-by-side comparison of Mastercard Incorporated and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Mastercard Incorporated · Financial Services
$574.42
+25.0% upside to fair value
Med Conviction
Grade A-
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MA has more upside to fair value
(+25.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MA |
MRK |
| Current Price |
$574.42 |
$147.17 |
| Fair Value Estimate |
$718.00 |
$141.07 |
| Upside to Fair Value |
+25.0%
|
-4.1%
|
| Market Cap |
$503.8B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
23.4x
|
29.6x
|
| Price / Sales |
14.4x
|
5.5x
|
| Price / FCF |
30.8x
|
22.6x
|
| Revenue Growth YoY |
+14.1%
|
+5.1%
|
| Gross Margin |
100%
|
75.4%
|
| Operating Margin |
59.8%
|
16.7%
|
| Return on Equity |
232.5%
|
6.6%
|
| Dividend Yield |
0.59% |
2.31% |
| FCF Yield |
3.25%
|
4.42%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Mastercard operates a global payments network that connects issuers, acquirers, merchants and consumers across more than 200 countries and territories, monetizing payment volumes, cross-border activity and higher-growth value-added services. Business quality is high because its two-sided network, trusted authorization-clearing-settlement infrastructure, brand, security capabilities and broad acce…
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
MA |
MRK |
| Zone Low |
$538.50 |
$105.80 |
| Zone High |
$610.30 |
$119.91 |
| In Buy Zone? |
Yes
|
No
|